Jianlin Chen,Yunmian Chu,Jin He,Lei Zheng,Xu Che. Precision medicine in the treatment of pancreatic ductal adenocarcinoma. Oncol Transl Med, 2016, 2: 150-155.
Precision medicine in the treatment of pancreatic ductal adenocarcinoma
Received:May 05, 2016  Revised:August 04, 2016
View Full Text  View/Add Comment  Download reader
KeyWord:pancreatic ductal adenocarcinoma (PDAC); precision medicine; chemotherapy; immunotherapy; cancer genomics
Author NameAffiliationE-mail
Jianlin Chen Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China jchen216@jhmi.edu 
Yunmian Chu Department of Abdominal Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Perking Union Medical College, Beijing 100021, China Yunmian.Chu@cicams.ac.cn 
Jin He Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States jhe11@jhmi.edu 
Lei Zheng Department of Oncology, The Sidney Kimmel Cancer Center, Department of Surgery, The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States lzheng6@jhmi.edu 
Xu Che Department of Abdominal Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Perking Union Medical College, Beijing 100021, China xu.che@cicams.ac.cn 
Hits: 6399
Download times: 7626
Abstract:
      Pancreatic cancer has a poor prognosis. Current therapies for pancreatic cancer have limited effects. In the past decade, precision medicine has shown great potential for clinical applications. In this review, different strategies for applying precision medicine to the treatment of pancreatic cancer are described.
Close